Exhibit 99.1
Terns Pharmaceuticals Reports Second Quarter 2022 Financial Results and Corporate Highlights
FOSTER CITY, Calif., August 8, 2022 – Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today reported financial results for the second quarter ended June 30, 2022 and corporate highlights.
“During the second quarter, Terns saw significant progress in advancing three of our internally discovered, small-molecule product candidates towards key clinical readouts in chronic myeloid leukemia, obesity and NASH,” said Sen Sundaram, chief executive officer at Terns. “We look forward to assessing the differentiation of these three product candidates, each of which target clinically validated mechanisms of action.”
Recent Developments and Anticipated Milestones
TERN-701: Oral, allosteric BCR-ABL tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia
TERN-601: Oral, small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist for obesity
TERN-501: Oral, thyroid hormone receptor-beta (THR-β) agonist for NASH
Key Appointments
Upcoming Investor Events
Second Quarter 2022 Financial Results
Terns Pharmaceuticals, Inc.
Condensed Consolidated Statements of Operations
(Unaudited; in thousands except share and per share amounts)
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
8,662 |
|
|
$ |
5,961 |
|
|
$ |
16,798 |
|
|
$ |
14,696 |
|
General and administrative |
|
|
5,422 |
|
|
|
4,857 |
|
|
|
11,111 |
|
|
|
9,418 |
|
Total operating expenses |
|
|
14,084 |
|
|
|
10,818 |
|
|
|
27,909 |
|
|
|
24,114 |
|
Loss from operations |
|
|
(14,084 |
) |
|
|
(10,818 |
) |
|
|
(27,909 |
) |
|
|
(24,114 |
) |
Interest income |
|
|
214 |
|
|
|
55 |
|
|
|
283 |
|
|
|
66 |
|
Other (expense) income, net |
|
|
(54 |
) |
|
|
39 |
|
|
|
(50 |
) |
|
|
26 |
|
Loss before income taxes |
|
|
(13,924 |
) |
|
|
(10,724 |
) |
|
|
(27,676 |
) |
|
|
(24,022 |
) |
Income tax expense |
|
|
(6 |
) |
|
|
(14 |
) |
|
|
(27 |
) |
|
|
(53 |
) |
Net loss |
|
$ |
(13,930 |
) |
|
$ |
(10,738 |
) |
|
$ |
(27,703 |
) |
|
$ |
(24,075 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.55 |
) |
|
$ |
(0.43 |
) |
|
$ |
(1.10 |
) |
|
$ |
(1.19 |
) |
Weighted average common stock outstanding, basic and diluted |
|
|
25,304,290 |
|
|
|
25,109,973 |
|
|
|
25,286,877 |
|
|
|
20,162,496 |
|
Terns Pharmaceuticals, Inc.
Selected Balance Sheet Data
(Unaudited; in thousands)
|
|
June 30, 2022 |
|
|
December 31, 2021 |
|
||
Cash, cash equivalents and marketable securities |
|
$ |
139,810 |
|
|
$ |
165,982 |
|
Total assets |
|
|
144,860 |
|
|
|
168,070 |
|
Total liabilities |
|
|
7,644 |
|
|
|
7,767 |
|
Total stockholders’ equity |
|
|
137,216 |
|
|
|
160,303 |
|
About Terns Pharmaceuticals
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH. Terns’ pipeline includes four clinical stage development programs including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Terns Pharmaceuticals, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s expectations of timing and potential results of the Company’s clinical trials and other development activities; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company’s small-molecule product candidates; the potential for the mechanisms of action of the Company’s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company’s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company’s clinical trials; the Company’s clinical development plans and activities; the Company’s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company’s plans for and ability to continue to execute on its current development strategy; and the Company’s expectations with regard to its runway. All statements other than statements of historical facts contained in this press release, including statements regarding the Company’s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company’s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company’s current and future research and development activities and preclinical studies and clinical trials. In particular, the impact of the COVID-19 pandemic on the Company’s ability to progress with its research, development, manufacturing and regulatory efforts, including the Company’s clinical trials for its product candidates, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States and in other countries, and the effectiveness of actions taken globally to contain and treat the disease. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the period ended March 31, 2022. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Contacts for Terns
Investors
Justin Ng
investors@ternspharma.com
Media
Jenna Urban
Berry & Company Public Relations
media@ternspharma.com